Avita Medical, Inc. (AVHHL) — SEC Filings
Avita Medical, Inc. (AVHHL) — 27 SEC filings. Latest: 10-Q (Nov 6, 2025). Includes 15 8-K, 6 10-Q, 2 DEF 14A.
View Avita Medical, Inc. on SEC EDGAR
Overview
Avita Medical, Inc. (AVHHL) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 6, 2025: AVITA Medical, Inc. reported a net loss of $13.187 million for the three months ended September 30, 2025, an improvement from the $16.205 million net loss in the prior-year period. For the nine months ended September 30, 2025, the net loss was $36.966 million, significantly better than the $50.256 m
Sentiment Summary
Across 27 filings, the sentiment breakdown is: 1 bullish, 24 neutral, 2 mixed. The dominant filing sentiment for Avita Medical, Inc. is neutral.
Filing Type Overview
Avita Medical, Inc. (AVHHL) has filed 6 10-Q, 15 8-K, 2 DEF 14A, 2 10-K, 2 SC 13G with the SEC between Jan 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (27)
Risk Profile
Risk Assessment: Of AVHHL's 22 recent filings, 1 were flagged as high-risk, 16 as medium-risk, and 5 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $17.062M |
| Net Income | -$13.187M |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $15.422M |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | $42.449M |
Key Executives
- Dr. Michelle Carpenter
- Dr. David L. Smith
- Dr. Michael J. R. Hall
- Dr. Stuart A. Holder
- Dr. Michael W. Ryan
- Ms. Jennifer L. Johnson
- Mr. David M. D. Smith
Industry Context
AVITA Medical operates in the acute wound care market, focusing on advanced regenerative medicine solutions. The market is characterized by a need for improved healing outcomes and reduced recovery times for patients with severe burns and skin defects. Key competitors may include companies offering traditional wound dressings, skin grafts, and other regenerative therapies. Regulatory approvals, such as those from the FDA, are critical for market entry and product differentiation.
Top Tags
financials (5) · 10-Q (4) · medical-devices (4) · Medical Devices (3) · filing (3) · material-agreement (3) · management-change (3) · AVITA Medical (3) · Biotechnology (2) · compensation (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss (Q3 2025) | $13.187M | Improved from $16.205M in Q3 2024 |
| Net Loss (9M 2025) | $36.966M | Improved from $50.256M in 9M 2024 |
| Total Revenues (Q3 2025) | $17.062M | Decreased from $19.546M in Q3 2024 |
| Total Revenues (9M 2025) | $53.995M | Increased from $45.845M in 9M 2024 |
| Total Operating Expenses (Q3 2025) | $23.028M | Decreased from $30.162M in Q3 2024 |
| Cash and Cash Equivalents (Sep 30, 2025) | $15.422M | Increased from $14.050M at Dec 31, 2024 |
| Proceeds from Private Placement | $14.792M | Contributed to increased cash balance |
| Loan Facility (Sep 30, 2025) | $42.449M | New debt on the balance sheet |
| Total Current Liabilities (Sep 30, 2025) | $61.831M | Exceeds current assets, indicating negative working capital |
| Common Shares Outstanding (Sep 30, 2025) | 30,493,111 | Increased from 26,354,042 at Dec 31, 2024 |
| Shares Sold | 1,000,000 | Under unregistered sale of equity securities |
| Price Per Share | $1.50 | For unregistered sale of equity securities |
| Gross Proceeds | $1.5 million | Expected from the unregistered sale of equity securities |
| SEC File Number | 001-39059 | Identifies the company's filing with the SEC. |
| IRS Employer Identification No. | 85-1021707 | Company's tax identification number. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Avita Medical, Inc. (AVHHL)?
Avita Medical, Inc. has 27 recent SEC filings from Jan 2024 to Nov 2025, including 15 8-K, 6 10-Q, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of AVHHL filings?
Across 27 filings, the sentiment breakdown is: 1 bullish, 24 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Avita Medical, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Avita Medical, Inc. (AVHHL) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Avita Medical, Inc.?
Key financial highlights from Avita Medical, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for AVHHL?
The investment thesis for AVHHL includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Avita Medical, Inc.?
Key executives identified across Avita Medical, Inc.'s filings include Dr. Michelle Carpenter, Dr. David L. Smith, Dr. Michael J. R. Hall, Dr. Stuart A. Holder, Dr. Michael W. Ryan and 2 others.
What are the main risk factors for Avita Medical, Inc. stock?
Of AVHHL's 22 assessed filings, 1 were flagged high-risk, 16 medium-risk, and 5 low-risk.
What are recent predictions and forward guidance from Avita Medical, Inc.?
Forward guidance and predictions for Avita Medical, Inc. are extracted from SEC filings as they are enriched.